Congress leader Manish Tewari on Tuesday said that the Bharatiya Janata Party (BJP) government has "politically misused" the COVID-19 pandemic and raised question marks on the reliability of the vaccine.
"The BJP government has politically misused the COVID-19 pandemic in its entirety. The controversy over the vaccine is its latest manifestation. Who is going to get himself vaccinated with a vaccine that has question marks on its reliability," Tewari said.
"The BJP govt has done a great disservice to that company which must have invested crores of rupees in research and development. In their quest to prove their 'Atmanirbhar Bharat' they have licensed a vaccine whose phase III trials are not complete," he added.
Earlier on January 2, Akhilesh Yadav had said that he will not get vaccinated against coronavirus for now as the "BJP government cannot be trusted".
Meanwhile, Serum Institute of India and Bharat Biotech jointly communicated their pledge on Tuesday for the smooth rollout of COVID-19 vaccines to India and the world.
"Mr. Adar Poonawala and Dr. Krishna Ella, jointly on behalf of the two companies, today communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines for India and globally," read a joint statement from SII and Bharat Biotech.
Adar Poonawala is Chief Executive Officer of SII. Dr. Krishna Ella is Chairman and Managing Director of Bharat Biotech.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)